177 related articles for article (PubMed ID: 30133305)
21. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
22. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models.
Dadachova E; Bryan RA; Frenkel A; Zhang T; Apostolidis C; Nosanchuk JS; Nosanchuk JD; Casadevall A
Antimicrob Agents Chemother; 2004 Mar; 48(3):1004-6. PubMed ID: 14982795
[TBL] [Abstract][Full Text] [Related]
24. Radiolabeled Antibodies for Therapy of Infectious Diseases.
Dadachova E; Casadevall A
Microbiol Spectr; 2014 Dec; 2(6):. PubMed ID: 26104440
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens.
Nosanchuk JD; Dadachova E
Front Microbiol; 2011; 2():283. PubMed ID: 22275913
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of infection with Bi-labeled antibodies.
Dadachova E
Curr Radiopharm; 2008 Sep; 1(3):234-239. PubMed ID: 20228957
[TBL] [Abstract][Full Text] [Related]
27. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.
Supiot S; Faivre-Chauvet A; Couturier O; Heymann MF; Robillard N; Kraeber-Bodéré F; Morandeau L; Mahé MA; Chérel M
Cancer; 2002 Feb; 94(4 Suppl):1202-9. PubMed ID: 11877746
[TBL] [Abstract][Full Text] [Related]
29. Targeting the virus with radioimmunotherapy in virus-associated cancers.
Dadachova E; Wang XG; Casadevall A
Cancer Biother Radiopharm; 2007 Jun; 22(3):303-8. PubMed ID: 17651036
[TBL] [Abstract][Full Text] [Related]
30. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
31. Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study.
Vandenbulcke K; Thierens H; Offner F; Janssens A; de Gelder V; Bacher K; Philippé J; De Vos F; Dierckx R; Apostolidis C; Morgenstern A; Slegers G
Nucl Med Commun; 2004 Nov; 25(11):1131-6. PubMed ID: 15577593
[TBL] [Abstract][Full Text] [Related]
32. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma.
Wang HY; Lin WY; Chen MC; Lin T; Chao CH; Hsu FN; Lin E; Huang CY; Luo TY; Lin H
Int J Radiat Biol; 2013 May; 89(5):346-55. PubMed ID: 23294030
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
35. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
Kinuya S; Yokoyama K; Izumo M; Sorita T; Obata T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Cancer Lett; 2005 Feb; 219(1):41-8. PubMed ID: 15694663
[TBL] [Abstract][Full Text] [Related]
36. Cancer radioimmunotherapy with alpha-emitting nuclides.
Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.
Bethge WA; Wilbur DS; Storb R; Hamlin DK; Santos EB; Brechbiel MW; Sandmaier BM
Transplantation; 2004 Aug; 78(3):352-9. PubMed ID: 15316362
[TBL] [Abstract][Full Text] [Related]
38. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
Wesley JN; McGee EC; Garmestani K; Brechbiel MW; Yordanov AT; Wu C; Gansow OA; Eckelman WC; Bacher JD; Flynn M; Goldman CK; MacLin M; Schwartz UP; Jackson-White T; Phillip CM; Decker J; Waldmann TA
Nucl Med Biol; 2004 Apr; 31(3):357-64. PubMed ID: 15028248
[TBL] [Abstract][Full Text] [Related]
39. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
Seitz U; Neumaier B; Glatting G; Kotzerke J; Bunjes D; Reske SN
Eur J Nucl Med; 1999 Oct; 26(10):1265-73. PubMed ID: 10541824
[TBL] [Abstract][Full Text] [Related]
40. Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.
Lucas S; Feron O; Gallez B; Masereel B; Michiels C; Vander Borght T
Comput Math Methods Med; 2015; 2015():284360. PubMed ID: 26136812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
